StreetInsider.com News Articles

Jefferies finds AI drives up to 50% cost cuts in drug development

Tue, 02 Jun 2026 12:32:48 -0400

Investing.com -- Jefferies released a research report Tuesday examining artificial intelligence adoption across pharmaceutical services companies, based on analysis of 42 expert call transcripts from the past 90 days.

The firm used AI tools to review commentary on AI implementation across contract research organizations and drug development processes. Expert identities were kept anonymous with only credentials provided.

The analysis found AI produces efficiency gains that vary by development stage. Early discovery and regulatory writing showed cost savings of approximately 40% to 50%, while preclinical workflows at CROs and contract development and manufacturing organizations saw time reductions of about 40% to 50%. Later-stage

Jefferies finds AI drives up to 50% cost cuts in drug development

Tue, 02 Jun 2026 12:32:48 -0400

Jefferies finds AI drives up to 50% cost cuts in drug development

Tue, 02 Jun 2026 12:32:48 -0400

Jefferies finds AI drives up to 50% cost cuts in drug development

Tue, 02 Jun 2026 12:32:48 -0400

Jefferies finds AI drives up to 50% cost cuts in drug development

Tue, 02 Jun 2026 12:32:48 -0400

Jefferies finds AI drives up to 50% cost cuts in drug development

Tue, 02 Jun 2026 12:32:48 -0400

Jefferies finds AI drives up to 50% cost cuts in drug development

Tue, 02 Jun 2026 12:32:48 -0400

Jefferies finds AI drives up to 50% cost cuts in drug development

Tue, 02 Jun 2026 12:32:48 -0400

Jefferies finds AI drives up to 50% cost cuts in drug development

Tue, 02 Jun 2026 12:32:48 -0400

Jefferies finds AI drives up to 50% cost cuts in drug development

Tue, 02 Jun 2026 12:32:48 -0400

Jefferies finds AI drives up to 50% cost cuts in drug development

Tue, 02 Jun 2026 12:32:48 -0400

Jefferies finds AI drives up to 50% cost cuts in drug development

Tue, 02 Jun 2026 12:32:48 -0400

Jefferies finds AI drives up to 50% cost cuts in drug development

Tue, 02 Jun 2026 12:32:48 -0400

Jefferies finds AI drives up to 50% cost cuts in drug development

Tue, 02 Jun 2026 12:32:48 -0400

Form 8-K WEST PHARMACEUTICAL SERV For: May 31

Mon, 01 Jun 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260601/26584356.html

Form 8-K WEST PHARMACEUTICAL SERV For: May 31

Mon, 01 Jun 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260601/26584356.html

Wolfe Research Assumes West Pharmaceutical (WST) at Outperform

Mon, 01 Jun 2026 16:31:26 -0400

(Updated - June 1, 2026 4:31 PM EDT)

Wolfe Research analyst Mike Polark assumes coverage on West Pharmaceutical (NYSE: WST) with a Outperform rating.

The analyst comments "We rate WST shares Outperform and have a $375 target price. This represents 40x our 2027 EPS estimate. A punchy input, we know – we unpack comfort/enthusiasm in subsequent paragraphs. However, relative to a history of premium absolute and relative valuation, this P/E input range isn’t completely offsides: (1) WST’s absolute P/E back ~15-years has average/median of 40x; (2) WST’s average premium to S&P 500 back 15-years is >100%; with S&P 500 here 22x NTM,

Wolfe Research Assumes West Pharmaceutical (WST) at Outperform

Mon, 01 Jun 2026 16:31:26 -0400

(Updated - June 1, 2026 4:31 PM EDT)

Wolfe Research analyst Mike Polark assumes coverage on West Pharmaceutical (NYSE: WST) with a Outperform rating.

West Pharmaceutical Services names Michel Lagarde as new CEO

Mon, 01 Jun 2026 16:30:16 -0400

West Pharmaceutical Services, Inc. (NYSE: WST) announced that its board of directors has appointed Michel Lagarde as president and chief executive officer, effective August 31, 2026. Lagarde will also join the company's board of directors on that date.

Lagarde succeeds Eric M. Green, who will retire from his roles as president, CEO and board chair on August 31, 2026. The board elected Lead Independent Director Robert F. Friel to become board chair, also effective August 31, 2026.

Lagarde most recently served as executive vice president and chief operating officer at Thermo Fisher Scientific, Inc., where he had responsibility for the majority of

West Pharmaceutical Services names Michel Lagarde as new CEO

Mon, 01 Jun 2026 16:30:16 -0400

Lagarde most recently served as executive vice president and chief operating officer at Thermo Fisher Scientific, Inc., where he had responsibility for the majority of

West Pharmaceutical Services names Michel Lagarde as new CEO

Mon, 01 Jun 2026 16:30:16 -0400

Lagarde most recently served as executive vice president and chief operating officer at Thermo Fisher Scientific, Inc., where he had responsibility for the majority of

West Pharmaceutical Services names Michel Lagarde as new CEO

Mon, 01 Jun 2026 16:30:16 -0400

Lagarde most recently served as executive vice president and chief operating officer at Thermo Fisher Scientific, Inc., where he had responsibility for the majority of

West Appoints Michel Lagarde to be President and Chief Executive Officer

Mon, 01 Jun 2026 16:30:00 -0400

Experienced healthcare and life sciences executive to lead the Company's next phase of growth and innovation

EXTON, Pa., June 1, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that its Board of Directors has appointed Michel Lagarde to be President and Chief Executive Officer (CEO) and a member of the Company's Board of Directors starting August 31, 2026. He succeeds Eric M. Green, who will retire from his roles as President, CEO and Board Chair on that

West Appoints Michel Lagarde to be President and Chief Executive Officer

Mon, 01 Jun 2026 16:30:00 -0400

Experienced healthcare and life sciences executive to lead the Company's next phase of growth and innovation

West Appoints Michel Lagarde to be President and Chief Executive Officer

Mon, 01 Jun 2026 16:30:00 -0400

Experienced healthcare and life sciences executive to lead the Company's next phase of growth and innovation